Industry and Technology Minister Mustafa Varank announced that Phase 1 vaccinations have been completed in the virus-like particles-based (VLP) vaccine candidate, which he also volunteered at the Phase 2 stage. Noting that they are planning to start Phase 3 studies of the domestic VLP vaccine in September, Minister Varank said that no side effects have been seen so far.
Emphasizing that more volunteers will be needed in the Phase 3 phase of human trials, Varank said, “Our healthcare workers continue vaccinations with great devotion. Of course, we strongly recommend that everyone be vaccinated. We invite our citizens who are waiting for the local vaccine to volunteer for this innovative vaccine.” said.
EMERGENCY USE APPROVAL
Varank, who also shared on his social media account, said, "We have completed another important stage in the VLP vaccine that I volunteered for.
Phase 2 vaccinations were also successfully completed without any side effects. We aim to reach a sufficient number of volunteers in the Phase 3 studies, which will start in September, and to obtain emergency use approval.” gave your message.
SUCCESSFULLY RESULTED
Prof. from METU. Dr. Another stage is left behind in the VLP vaccine candidate, which was developed by the joint project of Mayda Gürsel and İhsan Gürsel from Bilkent University. The clinical trial Phase 19 vaccinations of the VLP vaccine carried out under the roof of TÜBİTAK COVID-2 Turkey Platform have been successfully concluded.
AN INNOVATIVE METHOD
Making evaluations on the subject, Minister of Industry and Technology Mustafa Varank said, “There are different vaccines that have been implemented in the world or are still being studied. Some of these include innovative technologies. Our VLP vaccine candidate draws attention as one of the vaccine candidates developed with an innovative method.” said.
5 VLP VACCINE CANDIDATES
Minister Varank explained that they implemented the TÜBİTAK COVID-19 Turkey Platform in line with the vision of the National Technology Move and said, “Our VLP vaccine candidate is one of the successful works on this platform. There are 5 VLP vaccine candidates that have reached the clinical stage in the world. Two of them are in Canada and one in the Netherlands. India, the USA and the UK are working together on another VLP vaccine. One of these 5 vaccine candidates is the work of our teachers Mayda and İhsan.” he said.
WE BELIEVE IN THIS POTENTIAL
Underlining that the domestic VLP vaccine has great potential from this point of view, Varank said, “We, as the ministry, believed in this potential. We voluntarily participated in the Phase 27 study, the first clinical trials of which started on March 1, together with our TUBITAK President Hasan Mandal.” said.
WAITING FOR THE DOMESTIC VACCINE
Varank explained that after Phase 1, Phase 2 vaccinations were successfully completed in the VLP vaccine candidate, “We are planning to start Phase 3 studies of the domestic VLP vaccine in September. We have not encountered any side effects or negative effects so far. We will need more volunteers in the Phase 3 phase of human trials. Our healthcare workers continue to vaccinate with great devotion. Of course, we strongly recommend that everyone be vaccinated. We invite our citizens who are waiting for the local vaccine to volunteer for this innovative vaccine.” he said.
LISTED ON MARCH 30
The vaccine candidate, which is one of the few in the world and developed with the only VLP technology within the scope of the TUBITAK COVID-19 Turkey Platform, was included in the list of Covid-30 vaccine candidates of the World Health Organization (WHO) on March 19.
1 PEOPLE ATTENDED PHASE 36
1 people participated in the Phase 36 phase, where the VLP vaccine candidate, Minister Varank and TUBITAK President Mandal, volunteered. The Independent Data Monitoring Committee, consisting of 2 infectious diseases specialists and one pharmacologist, immunologist and statistician, approved the studies. Thereupon, an application was made to the Turkish Medicines and Medical Devices Agency for Phase 2.
PHASE 3 STUDY IN 2 CENTERS
With the approval of the study, Phase 26 was started on 2 June in 3 different centers. Dr. Two doses were given to 349 volunteers at Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Istanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital and Kocaeli University Medical Faculty Hospital. Vaccinations were completed on 8 August. The domestic VLP vaccine candidate's Phase 3 dossier is scheduled to be submitted in the third week of September.
IMITING THE VIRUS
In VLP vaccines, the developed virus-like particles mimic the virus in a non-infectious way. While these particles evoke an immune response, they do not cause disease.
USES 4 PROTEINS AS ANTIGENS
Another feature of the domestic VLP vaccine candidate is that, unlike other VLP vaccines, all 4 structural proteins of the virus are used as vaccine antigens in its design. With this feature, it is predicted that the domestic VLP vaccine candidate will provide a much more effective immunity against the virus.
Be the first to comment